Please ensure Javascript is enabled for purposes of website accessibility

Why Flexion Therapeutics Inc. Stock Is Tanking

By Brian Feroldi – Apr 26, 2017 at 11:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares dropped after the biotech announced plans to raise more than $100 million through a convertible bond offering.

What happened

After announcing that it would be raising capital in the form of convertible bond offering, shares of Flexion Therapeutics (FLXN) have fallen 15% as of 11:15 a.m. EDT. 

Falling stock chart

Image source: Getty Images.

So what

Flexion stated that it will be raising up to $125 million through a private convertible senior notes offering. The notes are set to mature in 2024. Flexion also said that it plans on granting the initial purchasers of the notes a 30-day option to purchase up to $18.75 million more to cover any over-allotments. The notes can be converted into cash, stock, or a combination of the two at the option of the holder. 

Management said that the proceeds from the offering will be used for the potential commercialization and manufacture of Zilretta, which is the company's lead compound that is pending approval as a treatment for osteoarthritis knee pain. Flexion also said the funds could be used for general corporate purposes, which could include acquisitions.

Now what

Flexion's cash balance at year end was $210 million while its total net loss for all of 2016 was $72 million. Those numbers suggest that Flexion has enough capital on hand to keep its doors open for nearly three full years. Perhaps that's why some shareholders are scratching their heads today as to why this company felt the need to raise additional capital.

It is also possible that some traders are interpreting this capital raise as proof that Sanofi won't be pursuing an acquisition. Flexion's shares jumped in March after a report by Fierce Pharma suggested that Sanofi was willing to spend more than $1 billion to buy Flexion. If that deal had merit, then Flexion would have no need to raise capital. 

Regardless of the short-term price action, shareholders should remember that Zilretta's PDUFA date is Oct. 6, 2017, and if all goes well, then management plans on launching the drug soon after approval. With some analysts calling for hundreds of millions of dollars in peak sales, Zilretta could single-handedly turn Flexion profitable. Thus, if you were bullish on Flexion's stock yesterday, I see no reason to change your stance based on today's news.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.